Improving the safety of systemic viral gene therapy
- PMID: 38165031
- PMCID: PMC10760946
- DOI: 10.1172/JCI177078
Improving the safety of systemic viral gene therapy
Conflict of interest statement
Comment on
-
Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.J Clin Invest. 2024 Jan 2;134(1):e173510. doi: 10.1172/JCI173510. J Clin Invest. 2024. PMID: 37988172 Free PMC article.
References
-
- FDA. Approved Cellular and Gene Therapy Producsts. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... Updated June 30, 2023. Accessed November 6, 2023.